Live from the 2018 San Antonio Breast Cancer Symposium, Breastcancer.org Chief Medical Officer Dr. Marisa Weiss discusses the results of the GEICAM study, which showed that patients with a certain type of triple-negative breast cancer (called “non-basal”) may benefit from extended treatment with Xeloda (capecitabine).